University of Connecticut, Department of Pharmaceutical Sciences, Storrs, CT 06269, United States.
FDA/CDER, Office of Generic Drugs, Office of Research and Standards, Silver Spring, MD 20993, United States.
Int J Pharm. 2021 Dec 15;610:121265. doi: 10.1016/j.ijpharm.2021.121265. Epub 2021 Nov 5.
Owing to their inherent heterogeneity, determination of similarity of poly (lactic-co-glycolic acid) (PLGA) polymers is very challenging. The complexity in controlling PLGA characteristics has been recognized as an obstacle to the development of PLGA based long-acting complex drug products (such as microspheres). The objectives of the present study were: (1) to determine minor differences in the physicochemical characteristics (such as inherent viscosity, molecular weight (Mw), monomer ratio (L/G ratio), glass transition temperature (Tg), and blockiness) as well as in the hydrolytic degradation profiles of PLGAs from different sources; and (2) to investigate the impact of PLGAs from different sources on the properties and in vitro performance of risperidone microspheres. Four PLGA polymers were purchased from different sources with similar inherent viscosity and/or Mw, L/G ratio and end groups as per the manufacturers' certificate of analysis (CoA). The physicochemical properties of these PLGAs were characterized using the same in-house methods and exhibited differences in inherent viscosity, Mw, blockiness and residue amount. Risperidone was chosen as the model drug and four microsphere formulations were prepared via the same solvent extraction/evaporation method using the PLGAs from different sources. The critical quality attributes of the microspheres (such as particle size, porosity and average pore diameter) and their in vitro release characteristics (burst effect and release rate) were shown to be different. A strong linear correlation was established between risperidone release and PLGA blockiness. This is the first time that such a correlation has been established, which promotes the potential need to further investigate the impact of PLGA blockiness on other PLGA based controlled release drug products.
由于其固有的异质性,确定聚(乳酸-共-乙醇酸)(PLGA)聚合物的相似性非常具有挑战性。控制 PLGA 特性的复杂性已被认为是开发基于 PLGA 的长效复杂药物产品(如微球)的障碍。本研究的目的是:(1)确定来自不同来源的 PLGA 在物理化学特性(如特性粘度、分子量(Mw)、单体比(L/G 比)、玻璃化转变温度(Tg)和嵌段性)以及水解降解谱方面的微小差异;(2)研究来自不同来源的 PLGA 对利培酮微球的性质和体外性能的影响。从不同来源购买了四种具有相似特性粘度和/或 Mw、L/G 比和端基的 PLGA 聚合物,符合制造商的分析证书(CoA)。使用相同的内部方法对这些 PLGA 的物理化学性质进行了表征,结果显示特性粘度、Mw、嵌段性和残留量存在差异。利培酮被选为模型药物,使用来自不同来源的 PLGA 通过相同的溶剂萃取/蒸发方法制备了四种微球制剂。微球的关键质量属性(如粒径、孔隙率和平均孔径)及其体外释放特性(突释效应和释放速率)存在差异。利培酮的释放与 PLGA 嵌段性之间建立了很强的线性相关性。这是首次建立这种相关性,这促进了进一步研究 PLGA 嵌段性对其他基于 PLGA 的控释药物产品的影响的潜在需求。